Articles

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome

Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Hematological Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Biostatistics, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Department of Leukemia, University of Texas MD Anderson Cancer Center
Haematologica Early view Apr 15, 2021 https://doi.org/10.3324/haematol.2020.263392